Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation.

Cohn LB, da Silva IT, Valieris R, Huang AS, Lorenzi JCC, Cohen YZ, Pai JA, Butler AL, Caskey M, Jankovic M, Nussenzweig MC.

Nat Med. 2018 May;24(5):604-609. doi: 10.1038/s41591-018-0017-7. Epub 2018 Apr 23.

PMID:
29686423
2.

Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity.

Dosenovic P, Kara EE, Pettersson AK, McGuire AT, Gray M, Hartweger H, Thientosapol ES, Stamatatos L, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4743-4748. doi: 10.1073/pnas.1803457115. Epub 2018 Apr 16.

PMID:
29666227
3.

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC, Martin MA.

Nat Med. 2018 May;24(5):610-616. doi: 10.1038/s41591-018-0001-2. Epub 2018 Apr 16.

PMID:
29662199
4.

Redemption for self-reactive antibodies.

Kara EE, Nussenzweig MC.

Science. 2018 Apr 13;360(6385):152-153. doi: 10.1126/science.aat5758. No abstract available.

PMID:
29650658
5.

Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope.

Barnes CO, Gristick HB, Freund NT, Escolano A, Lyubimov AY, Hartweger H, West AP Jr., Cohen AE, Nussenzweig MC, Bjorkman PJ.

Nat Commun. 2018 Mar 28;9(1):1251. doi: 10.1038/s41467-018-03632-y.

6.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B.

PLoS Pathog. 2018 Mar 5;14(3):e1006860. doi: 10.1371/journal.ppat.1006860. eCollection 2018 Mar.

7.

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.

Cohen YZ, Lorenzi JCC, Seaman MS, Nogueira L, Schoofs T, Krassnig L, Butler A, Millard K, Fitzsimons T, Daniell X, Dizon JP, Shimeliovich I, Montefiori DC, Caskey M, Nussenzweig MC.

J Virol. 2018 Feb 12;92(5). pii: e01883-17. doi: 10.1128/JVI.01883-17. Print 2018 Mar 1.

8.

The microanatomic segregation of selection by apoptosis in the germinal center.

Mayer CT, Gazumyan A, Kara EE, Gitlin AD, Golijanin J, Viant C, Pai J, Oliveira TY, Wang Q, Escolano A, Medina-Ramirez M, Sanders RW, Nussenzweig MC.

Science. 2017 Oct 13;358(6360). pii: eaao2602. doi: 10.1126/science.aao2602. Epub 2017 Sep 21.

9.

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.

Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW.

J Exp Med. 2017 Sep 4;214(9):2573-2590. doi: 10.1084/jem.20161160. Epub 2017 Aug 28.

10.

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC.

Cell. 2017 Aug 10;170(4):637-648.e10. doi: 10.1016/j.cell.2017.06.048. Epub 2017 Jul 27.

PMID:
28757252
11.

JEM Advisory Editorial Board: Increasing diversity.

Nathan C, Nussenzweig MC, Pulvirenti T.

J Exp Med. 2017 Jul 26. pii: jem.20171220. doi: 10.1084/jem.20171220. [Epub ahead of print] No abstract available.

12.

Correction: RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks.

Rommel PC, Oliveira TY, Nussenzweig MC, Robbiani DF.

J Exp Med. 2017 Jul 3;214(7):2167. doi: 10.1084/jem.2016163806092017c. Epub 2017 Jun 15. No abstract available.

13.

Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.

Wang H, Gristick HB, Scharf L, West AP, Galimidi RP, Seaman MS, Freund NT, Nussenzweig MC, Bjorkman PJ.

Elife. 2017 May 26;6. pii: e27389. doi: 10.7554/eLife.27389.

14.

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.

Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R, Azzopardi SA, Uhl LFK, Saeed M, Sevilla-Reyes EE, Agudelo M, Yao KH, Golijanin J, Gristick HB, Lee YE, Hurley A, Caskey M, Pai J, Oliveira T, Wunder EA Jr., Sacramento G, Nery N Jr., Orge C, Costa F, Reis MG, Thomas NM, Eisenreich T, Weinberger DM, de Almeida ARP, West AP Jr., Rice CM, Bjorkman PJ, Reyes-Teran G, Ko AI, MacDonald MR, Nussenzweig MC.

Cell. 2017 May 4;169(4):597-609.e11. doi: 10.1016/j.cell.2017.04.024.

15.

HIV: Persistence through division.

Cohn LB, Nussenzweig MC.

J Exp Med. 2017 Apr 3;214(4):875-876. doi: 10.1084/jem.20170463. Epub 2017 Mar 27.

16.

Early antibody therapy can induce long-lasting immunity to SHIV.

Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA.

Nature. 2017 Mar 23;543(7646):559-563. doi: 10.1038/nature21435. Epub 2017 Mar 13.

17.

RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks.

Rommel PC, Oliveira TY, Nussenzweig MC, Robbiani DF.

J Exp Med. 2017 Mar 6;214(3):815-831. doi: 10.1084/jem.20161638. Epub 2017 Feb 8. Erratum in: J Exp Med. 2017 Jun 15;:.

18.

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP Jr, Bjorkman PJ, Nussenzweig MC.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaal2144. doi: 10.1126/scitranslmed.aal2144.

19.

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, Learn GH, Cohen YZ, Lehmann C, Gillor D, Shimeliovich I, Unson-O'Brien C, Weiland D, Robles A, Kümmerle T, Wyen C, Levin R, Witmer-Pack M, Eren K, Ignacio C, Kiss S, West AP Jr, Mouquet H, Zingman BS, Gulick RM, Keler T, Bjorkman PJ, Seaman MS, Hahn BH, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC, Klein F.

Nat Med. 2017 Feb;23(2):185-191. doi: 10.1038/nm.4268. Epub 2017 Jan 16.

20.

A time of change.

Nathan CF, Nussenzweig MC, Pulvirenti T.

J Exp Med. 2017 Jan;214(1):1-2. doi: 10.1084/jem.20162116.

21.

Progress toward active or passive HIV-1 vaccination.

Escolano A, Dosenovic P, Nussenzweig MC.

J Exp Med. 2017 Jan;214(1):3-16. doi: 10.1084/jem.20161765. Epub 2016 Dec 21. Review.

22.

The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into iNOS+ Macrophages or Monocyte-Derived Dendritic Cells.

Menezes S, Melandri D, Anselmi G, Perchet T, Loschko J, Dubrot J, Patel R, Gautier EL, Hugues S, Longhi MP, Henry JY, Quezada SA, Lauvau G, Lennon-Duménil AM, Gutiérrez-Martínez E, Bessis A, Gomez-Perdiguero E, Jacome-Galarza CE, Garner H, Geissmann F, Golub R, Nussenzweig MC, Guermonprez P.

Immunity. 2016 Dec 20;45(6):1205-1218. doi: 10.1016/j.immuni.2016.12.001.

23.

The cell cycle restricts activation-induced cytidine deaminase activity to early G1.

Wang Q, Kieffer-Kwon KR, Oliveira TY, Mayer CT, Yao K, Pai J, Cao Z, Dose M, Casellas R, Jankovic M, Nussenzweig MC, Robbiani DF.

J Exp Med. 2017 Jan;214(1):49-58. doi: 10.1084/jem.20161649. Epub 2016 Dec 20.

24.

Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.

Caskey M, Klein F, Nussenzweig MC.

N Engl J Med. 2016 Nov 24;375(21):2019-2021. Epub 2016 Nov 9. No abstract available.

PMID:
27959740
25.

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

Lorenzi JC, Cohen YZ, Cohn LB, Kreider EF, Barton JP, Learn GH, Oliveira T, Lavine CL, Horwitz JA, Settler A, Jankovic M, Seaman MS, Chakraborty AK, Hahn BH, Caskey M, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7908-E7916. Epub 2016 Nov 21. Erratum in: Proc Natl Acad Sci U S A. 2017 Jan 17;:.

26.

Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs.

Breton G, Zheng S, Valieris R, Tojal da Silva I, Satija R, Nussenzweig MC.

J Exp Med. 2016 Dec 12;213(13):2861-2870. Epub 2016 Nov 18.

27.

Sequencing and cloning of antigen-specific antibodies from mouse memory B cells.

von Boehmer L, Liu C, Ackerman S, Gitlin AD, Wang Q, Gazumyan A, Nussenzweig MC.

Nat Protoc. 2016 Oct;11(10):1908-1923. doi: 10.1038/nprot.2016.102. Epub 2016 Sep 15.

PMID:
27658009
28.

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.

Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR.

Immunity. 2016 Sep 20;45(3):483-496. doi: 10.1016/j.immuni.2016.08.016. Epub 2016 Sep 8.

29.

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.

Gristick HB, von Boehmer L, West AP Jr, Schamber M, Gazumyan A, Golijanin J, Seaman MS, Fätkenheuer G, Klein F, Nussenzweig MC, Bjorkman PJ.

Nat Struct Mol Biol. 2016 Oct;23(10):906-915. doi: 10.1038/nsmb.3291. Epub 2016 Sep 12.

30.

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, Freund NT, Gitlin AD, Oliveira T, Araki T, Lowe S, Chen ST, Heinemann J, Yao KH, Georgeson E, Saye-Francisco KL, Gazumyan A, Adachi Y, Kubitz M, Burton DR, Schief WR, Nussenzweig MC.

Cell. 2016 Sep 8;166(6):1445-1458.e12. doi: 10.1016/j.cell.2016.07.030.

31.

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen YZ, Hadrigan S, Settler A, Witmer-Pack M, West AP Jr, Juelg B, Keler T, Hawthorne T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman MS, Bjorkman PJ, Klein F, Schlesinger SJ, Walker BD, Hahn BH, Nussenzweig MC, Caskey M.

Nature. 2016 Jul 28;535(7613):556-60. Epub 2016 Jun 22.

32.

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV.

Cell. 2016 Jun 16;165(7):1609-1620. doi: 10.1016/j.cell.2016.04.050.

33.

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A, Ravetch JV, Caskey M, Chakraborty AK, Nussenzweig MC.

Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.

34.

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JC, Parrish EH, Learn GH, West AP Jr, Bjorkman PJ, Schlesinger SJ, Seaman MS, Czartoski J, McElrath MJ, Pfeifer N, Hahn BH, Caskey M, Nussenzweig MC.

Science. 2016 May 20;352(6288):997-1001. doi: 10.1126/science.aaf0972. Epub 2016 May 5.

35.

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.

Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, Mankoff Z, Schmidt SD, Lifson JD, Mascola JR, Nussenzweig MC, Martin MA.

Nature. 2016 May 5;533(7601):105-109. doi: 10.1038/nature17677. Epub 2016 Apr 27.

36.

Inducible targeting of cDCs and their subsets in vivo.

Loschko J, Rieke GJ, Schreiber HA, Meredith MM, Yao KH, Guermonprez P, Nussenzweig MC.

J Immunol Methods. 2016 Jul;434:32-8. doi: 10.1016/j.jim.2016.04.004. Epub 2016 Apr 9.

37.

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS.

PLoS Pathog. 2016 Mar 30;12(3):e1005520. doi: 10.1371/journal.ppat.1005520. eCollection 2016 Mar.

38.

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2016 Jul 28;535(7613):580. doi: 10.1038/nature17642. Epub 2016 Mar 23. No abstract available.

PMID:
27007847
39.

Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation.

Loschko J, Schreiber HA, Rieke GJ, Esterházy D, Meredith MM, Pedicord VA, Yao KH, Caballero S, Pamer EG, Mucida D, Nussenzweig MC.

J Exp Med. 2016 Apr 4;213(4):517-34. doi: 10.1084/jem.20160062. Epub 2016 Mar 21.

40.

Structural basis for germline antibody recognition of HIV-1 immunogens.

Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ.

Elife. 2016 Mar 21;5. pii: e13783. doi: 10.7554/eLife.13783.

41.

Human studies at JEM: Immunology and beyond.

Casanova JL, Nathan CF, Nussenzweig MC; Editors.

J Exp Med. 2016 Apr 4;213(4):467-8. doi: 10.1084/jem.20160211. Epub 2016 Mar 14. No abstract available.

42.

Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory.

Gitlin AD, von Boehmer L, Gazumyan A, Shulman Z, Oliveira TY, Nussenzweig MC.

Immunity. 2016 Apr 19;44(4):769-81. doi: 10.1016/j.immuni.2016.01.011. Epub 2016 Mar 2.

43.

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L.

Nat Commun. 2016 Feb 24;7:10618. doi: 10.1038/ncomms10618.

44.

A New Way to Diversify Antibodies by DNA Transposition.

Robbiani DF, Nussenzweig MC.

Cell. 2016 Feb 11;164(4):601-2. doi: 10.1016/j.cell.2016.01.031.

45.

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Halper-Stromberg A, Nussenzweig MC.

J Clin Invest. 2016 Feb;126(2):415-23. doi: 10.1172/JCI80561. Epub 2016 Jan 11. Review.

46.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC.

PLoS Pathog. 2015 Oct 30;11(10):e1005238. doi: 10.1371/journal.ppat.1005238. eCollection 2015 Oct.

47.

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.

Morgand M, Bouvin-Pley M, Plantier JC, Moreau A, Alessandri E, Simon F, Pace CS, Pancera M, Ho DD, Poignard P, Bjorkman PJ, Mouquet H, Nussenzweig MC, Kwong PD, Baty D, Chames P, Braibant M, Barin F.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):237-45. doi: 10.1097/QAI.0000000000000854.

48.

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.

Lee JH, Leaman DP, Kim AS, Torrents de la Peña A, Sliepen K, Yasmeen A, Derking R, Ramos A, de Taeye SW, Ozorowski G, Klein F, Burton DR, Nussenzweig MC, Poignard P, Moore JP, Klasse PJ, Sanders RW, Zwick MB, Wilson IA, Ward AB.

Nat Commun. 2015 Sep 25;6:8167. doi: 10.1038/ncomms9167.

49.

Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching.

Dong J, Panchakshari RA, Zhang T, Zhang Y, Hu J, Volpi SA, Meyers RM, Ho YJ, Du Z, Robbiani DF, Meng F, Gostissa M, Nussenzweig MC, Manis JP, Alt FW.

Nature. 2015 Sep 3;525(7567):134-139. doi: 10.1038/nature14970. Epub 2015 Aug 26.

50.

Defining human dendritic cell progenitors by multiparametric flow cytometry.

Breton G, Lee J, Liu K, Nussenzweig MC.

Nat Protoc. 2015 Sep;10(9):1407-22. doi: 10.1038/nprot.2015.092. Epub 2015 Aug 20.

Supplemental Content

Loading ...
Support Center